Hepatic Encephalopathy
Critical Alerts
- Must identify and treat precipitants: Infection (SBP), GI bleed, constipation, medications
- Ammonia level doesn't correlate with severity: Clinical assessment is paramount
- Risk of cerebral edema in acute liver failure: Different from chronic HE
- Differentiate from other causes of AMS: Infection, intoxication, stroke, hypoglycemia
- Lactulose is first-line treatment: Goal is 2-3 soft stools daily
- Check for infection: SBP is common precipitant in cirrhosis
Key Diagnostics
| Test | Finding | Significance |
|---|---|---|
| Ammonia | May be elevated | Doesn't correlate with severity; not required |
| CBC | Leukocytosis | May indicate infection |
| CMP | Electrolytes, glucose, renal function | Precipitant identification |
| LFTs | Elevated bilirubin, low albumin | Assess liver function |
| INR | Prolonged | Synthetic dysfunction |
| Blood cultures | Positive | Sepsis |
| Urinalysis | UTI | Common precipitant |
| Diagnostic paracentesis | PMN >50/μL | SBP diagnosis |
Emergency Treatments
| Condition | Treatment | Dose |
|---|---|---|
| First-line | Lactulose | 30-45 mL PO q1-2h until bowel movement, then TID-QID |
| Rectal if unable to take PO | Lactulose enema | 300 mL in 700 mL water |
| Adjunctive | Rifaximin | 550 mg PO BID |
| Infection | Antibiotics | Ceftriaxone 2g IV for presumed SBP |
| GI bleeding | PPI, octreotide | Standard variceal bleed management |
| Hypoglycemia | D50 | 50 mL IV |
Overview
Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities occurring in patients with liver dysfunction, resulting from the accumulation of neurotoxins (primarily ammonia) that bypass hepatic metabolism. It ranges from subtle cognitive changes to deep coma and is usually precipitated by identifiable factors in patients with chronic liver disease.
Classification
By Type:
| Type | Setting |
|---|---|
| Type A | Acute liver failure (different physiology) |
| Type B | Portosystemic bypass without intrinsic liver disease |
| Type C | Cirrhosis (most common) |
By Severity (West Haven Criteria):
| Grade | Description | Findings |
|---|---|---|
| Covert (MHE + Grade I) | Minimal or subclinical | Psychometric testing abnormal; mild confusion |
| Grade I | Mild | Shortened attention span, altered sleep, euphoria/anxiety |
| Grade II | Moderate | Lethargy, disorientation to time, personality change, asterixis |
| Grade III | Severe | Somnolence but arousable, gross disorientation, bizarre behavior |
| Grade IV | Coma | Unresponsive to stimuli |
By Course:
- Episodic: Single episode with precipitant
- Recurrent: Multiple episodes within 6 months
- Persistent: Persistent cognitive impairment despite treatment
Epidemiology
- Prevalence in cirrhosis: 30-45% will have overt HE at some point
- Minimal HE: Present in 20-80% of cirrhotics (often undiagnosed)
- Hospital readmissions: HE is leading cause of readmission in cirrhosis
- Mortality: 30-50% 1-year mortality after first episode of overt HE
Etiology
Precipitating Factors (Most Important to Identify):
| Precipitant | Frequency | Mechanism |
|---|---|---|
| Infection (including SBP) | 25-30% | Increased nitrogen load, inflammation |
| GI bleeding | 20-25% | Protein load from blood in gut |
| Constipation | 15-20% | Increased ammonia production and absorption |
| Dehydration/Electrolyte disturbance | 15% | Hypokalemia, hyponatremia |
| Medications (sedatives, opioids) | 10-15% | Direct CNS effect |
| Dietary protein excess | 5% | Increased nitrogen load (less common) |
| Renal failure | Variable | Decreased ammonia clearance |
| TIPS placement | Variable | Increased portosystemic shunting |
| Non-compliance with lactulose | Common | Clear history of stopping medications |
| Unknown/No identifiable precipitant | 20-30% |
Ammonia Hypothesis
- Ammonia production: Gut bacteria break down nitrogenous compounds
- Normally cleared by liver: Via urea cycle
- In liver failure/shunting: Ammonia bypasses liver, enters systemic circulation
- Crosses blood-brain barrier: Enters astrocytes
- Astrocyte swelling: Glutamine accumulation causes osmotic swelling
- Neurological dysfunction: Impaired neurotransmission, inflammation
Other Contributing Factors
- Inflammation: Systemic inflammation from gut translocation amplifies ammonia's effects
- Manganese: Accumulates in basal ganglia
- GABA/Benzodiazepine-like substances: Enhanced GABAergic tone
- Altered amino acids: Increased aromatic, decreased branched-chain
- Oxidative stress: From multiple mechanisms
Differences: Acute Liver Failure vs Cirrhosis
| Feature | Acute Liver Failure (Type A) | Cirrhosis (Type C) |
|---|---|---|
| Cerebral edema | Common, life-threatening | Rare |
| ICP elevation | Yes | No |
| Ammonia level | Better correlate with severity | Poor correlation |
| Treatment focus | Prevent herniation, transplant | Treat precipitants, lactulose |
Symptoms
Covert/Minimal HE:
Overt HE:
| Stage | Symptoms |
|---|---|
| Grade I | Shortened attention, mood changes, sleep disturbance |
| Grade II | Obvious personality change, inappropriate behavior, lethargy |
| Grade III | Marked confusion, somnolence but arousable |
| Grade IV | Coma, unresponsive |
History
Key Questions:
Physical Examination
General:
Neurological:
| Finding | Description |
|---|---|
| Asterixis | "Liver flap" - involuntary tremor with dorsiflexion of wrists |
| Hyperreflexia | Early stages |
| Hyporeflexia | Late stages |
| Rigidity | Extrapyramidal signs |
| Fetor hepaticus | Musty, sweet breath odor |
| Constructional apraxia | Unable to draw star, copy figures |
Signs of Precipitating Factors:
Life-Threatening Conditions
| Finding | Concern | Action |
|---|---|---|
| Acute liver failure + HE | Cerebral edema, herniation | ICU, ICP monitoring, transplant eval |
| GCS ≤8 or rapidly declining | Airway at risk | Intubation, ICU |
| Fever + abdominal pain + ascites | SBP | Diagnostic paracentesis, antibiotics |
| Hematemesis/melena | Variceal bleeding | GI consultation, hemodynamic support |
| Hypoglycemia | Common in liver failure | D50 administration |
| Refractory to treatment | Alternative diagnosis or severe disease | Reassess, consider intubation |
Alternative Diagnoses to Consider
- Alcohol intoxication or withdrawal
- Hypoglycemia
- Infection/Sepsis (causing delirium)
- Stroke
- Subdural hematoma (especially if falls or anticoagulation)
- Medication overdose
- Wernicke's encephalopathy
- Uremia
AMS in Patients with Cirrhosis
| Diagnosis | Distinguishing Features | Evaluation |
|---|---|---|
| Hepatic encephalopathy | Liver stigmata, asterixis, precipitant identified | Clinical diagnosis |
| Alcohol withdrawal | Tremor, autonomic instability, timeline from last drink | CIWA score |
| Hypoglycemia | Symptoms improve with glucose | Fingerstick glucose |
| Infection/Sepsis | Fever, elevated WBC, source | Cultures, imaging |
| Subdural hematoma | Trauma history, focal signs, coagulopathic | CT head |
| Stroke | Focal deficits, acute onset | CT/MRI |
| Drug overdose | Known ingestion, toxidrome | Tox screen |
| Wernicke's | Ataxia, ophthalmoplegia, alcoholism | Clinical; give thiamine |
| Uremic encephalopathy | Elevated creatinine, ESRD | BMP |
| Postictal | Witnessed seizure | History, EEG if unclear |
Clinical Diagnosis
HE is a clinical diagnosis based on:
- Known liver disease or portal-systemic shunting
- Altered mental status (ranging from subtle to coma)
- Exclusion of other causes of AMS
- Identification of precipitant (if possible)
Laboratory Studies
| Test | Rationale | Notes |
|---|---|---|
| Ammonia | May support diagnosis | Does NOT correlate with severity; trend is more useful than single level |
| CBC | Infection, bleeding | Leukocytosis |
| CMP | Glucose, electrolytes, renal | Hyponatremia, hypoglycemia, AKI |
| LFTs | Liver synthetic function | Elevated bilirubin |
| PT/INR | Coagulopathy | Prolonged |
| Blood cultures | Sepsis | If fever or infection suspected |
| Urinalysis | UTI | Common precipitant |
| Lactate | Sepsis | Hypoperfusion |
Ammonia Interpretation:
- Elevated ammonia supports but does not confirm diagnosis
- Normal ammonia does not exclude HE
- Single values less useful than trends
- Do not use to titrate therapy
Diagnostic Paracentesis
Indications in HE:
- Any patient with ascites and AMS (to rule out SBP)
- Fever, abdominal pain, or tenderness
SBP Criteria:
- PMN count ≥250 cells/μL = SBP (treat empirically)
- Culture positive (may be delayed)
Imaging
CT Head:
- Not routinely needed for classic HE presentation
- Indicated if: Focal signs, head trauma, anticoagulated, atypical presentation
- Rule out stroke, SDH, other structural causes
Psychometric Testing (For Minimal HE)
- Number connection test
- Digit symbol test
- Critical flicker frequency
- Not practical in acute setting
Principles of Management
- Identify and treat precipitant (most important)
- Reduce ammonia levels via gut (lactulose)
- Supportive care (hydration, nutrition, airway)
- Consider rifaximin (adjunctive, reduces recurrence)
- Avoid sedatives (can worsen HE)
- Consider transplant evaluation for recurrent HE
Treat Precipitants
| Precipitant | Treatment |
|---|---|
| Infection/SBP | Ceftriaxone 2g IV; adjust for culture |
| GI bleeding | PPI, octreotide, urgent endoscopy |
| Constipation | Lactulose, enemas |
| Dehydration | IV fluids (avoid NS if possible - hyperchloremic acidosis) |
| Electrolyte disturbances | Correction (K+, Na+) |
| Medications | Hold sedatives, opioids, diuretics |
| Renal failure | Fluids, hold nephrotoxins, consider RRT |
Lactulose
First-Line Treatment:
| Route | Dose | Goal |
|---|---|---|
| Oral | 30-45 mL q1-2h until bowel movement, then TID-QID | 2-3 soft stools/day |
| Rectal (if unable to take PO) | 300 mL lactulose in 700 mL water as enema | Retain 30-60 min, repeat |
Mechanism:
- Decreases colonic pH → traps ammonia as ammonium (NH4+)
- Cathartic effect removes nitrogenous material
- Alters gut flora
Monitoring:
- Too few stools → inadequate treatment
- Excessive diarrhea → dehydration, hyponatremia, worsen HE
Rifaximin
Adjunctive Therapy:
| Dose | Indication |
|---|---|
| 550mg PO BID | Prevention of recurrent HE; adjunct in acute |
Mechanism:
- Non-absorbable antibiotic
- Reduces ammonia-producing gut bacteria
Evidence:
- Reduces recurrence by 50% when added to lactulose
- Expensive but effective
L-Ornithine L-Aspartate (LOLA)
- Increases ammonia metabolism
- Used in some countries
- Evidence is mixed
Airway Protection
- Intubate for GCS ≤8 or inability to protect airway
- Consider for Grade III-IV HE
- Avoid sedation if possible; use short-acting agents
Nutrition
- Do NOT restrict protein (causes muscle wasting, may worsen HE)
- Target 1.2-1.5 g/kg/day protein
- Consider branched-chain amino acids in intolerant patients
- Frequent small meals
Avoid Deleterious Medications
- Benzodiazepines
- Opioids
- Proton pump inhibitors (may increase SBP risk)
- Excessive diuretics (cause dehydration, hypokalemia)
Admission Criteria
- Grade II or higher HE (overt HE)
- Any HE with identified precipitant requiring treatment (GI bleed, SBP)
- Unable to take oral medications
- Inadequate home support
- Failure of outpatient management
ICU Criteria
- Grade III-IV HE with airway concerns
- Acute liver failure with HE
- Concurrent GI bleeding or septic shock
- Need for intubation
Discharge Criteria
- Mental status returned to baseline
- Precipitant treated
- Tolerating PO lactulose
- Adequate home support
- Follow-up arranged with hepatology
Follow-Up
| Situation | Follow-Up |
|---|---|
| First episode | Hepatology within 1-2 weeks |
| Recurrent HE | Hepatology urgent; transplant evaluation |
| On lactulose/rifaximin | Hepatology regular follow-up |
| Refractory | Consider embolization of shunts, transplant |
Condition Explanation
- "Your liver is not able to remove toxins from your blood effectively, and these toxins are affecting your brain."
- "This is treatable, but we need to find out what triggered this episode."
- "Lactulose works by helping your body get rid of these toxins through bowel movements."
Medication Instructions
Lactulose:
- Take as prescribed; do not stop without physician guidance
- Goal is 2-3 soft bowel movements per day
- Too few = underdose → confusion may return
- Too many = dehydration → confusion may worsen
- Sweet taste; can mix with juice
- If you can't take it orally, seek medical attention
Rifaximin:
- Take twice daily with or without food
- Prevents recurrence of confusion
- May be expensive; ask about patient assistance programs
Prevention Strategies
- Avoid constipation
- Stay hydrated
- Avoid sedatives, sleeping pills without physician approval
- Avoid excessive salt intake (worsens fluid retention)
- Maintain good nutrition
- Avoid alcohol completely
- Take medications as prescribed
Warning Signs Requiring Medical Attention
- Worsening confusion
- Increased sleepiness
- Blood in stool or vomiting blood
- Fever
- Abdominal pain or increased swelling
- Unable to take medications
- Falls
Acute Liver Failure (Type A HE)
- Different pathophysiology: Cerebral edema and elevated ICP are major concerns
- Requires ICU-level care
- ICP monitoring may be needed
- Consider mannitol or hypertonic saline for elevated ICP
- Liver transplant evaluation urgently
- Lactulose is still used but managing ICP is critical
Post-TIPS
- HE is a known complication of TIPS
- Occurs in 30-50% of patients
- May require TIPS reduction or embolization
- Manage with lactulose and rifaximin
Minimal Hepatic Encephalopathy
- Subclinical cognitive impairment
- May affect driving, work performance
- Treat with lactulose; rifaximin if needed
- Specialist follow-up
Elderly
- Higher mortality
- More likely to have medication precipitants
- Falls are common
- May need more support at home
Performance Indicators
| Metric | Target | Rationale |
|---|---|---|
| Precipitant identified | >0% | Treatment depends on cause |
| Lactulose initiated | 100% with overt HE | First-line therapy |
| Diagnostic paracentesis for HE + ascites | 100% | Rule out SBP |
| Alternative diagnoses excluded | 100% | HE is diagnosis of exclusion |
| Hepatology referral | 100% for new HE | Specialty care |
| Transplant evaluation for recurrent HE | >0% | May be only definitive treatment |
Documentation Requirements
- Mental status using standard grading
- Precipitant(s) identified or "unknown"
- Lactulose dosing and patient response
- Paracentesis results if performed
- Ammonia level (if obtained)
- Alternative diagnoses considered and excluded
- Discharge plan including medication instructions
Diagnostic Pearls
- HE is a clinical diagnosis: Ammonia level doesn't define or grade severity
- Always look for the precipitant: Treatment won't work without addressing it
- Paracentesis is mandatory: If ascites + AMS, rule out SBP
- Asterixis is not unique to HE: Also seen in uremia, hypoxia, sedatives
- Normal ammonia doesn't exclude HE: Clinical assessment is paramount
- Consider other diagnoses: Especially in cirrhosis (SDH from falls, intoxication)
Treatment Pearls
- Lactulose goal is 2-3 soft stools: Titrate accordingly
- Rectal lactulose works: If patient can't take PO
- Don't protein restrict: Actually harmful; maintain nutrition
- Rifaximin reduces recurrence: Consider adding for recurrent HE
- Treat the precipitant: Antibiotics for SBP, GI bleed management, etc.
- Avoid sedatives: Benzodiazepines worsen HE
Disposition Pearls
- Admit all overt HE (Grade II+): Need hospital management
- Transplant evaluation for recurrent: May be only cure
- Education is essential: Medication compliance prevents recurrence
- Family involvement: Patients may not recognize early symptoms
- Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735.
- Amodio P, et al. The nutritional management of hepatic encephalopathy. Hepatology. 2014;60(2):715-735.
- Montagnese S, et al. Sleep disturbance and hepatic encephalopathy. Metab Brain Dis. 2014;29(3):529-539.
- Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
- Cordoba J, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy. J Hepatol. 2014;60(2):275-281.
- Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol. 2011;7(4):222-233.
- Shawcross DL, et al. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis. 2005;20(3):169-179.
- UpToDate. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. 2024.